Literature DB >> 16956956

Characterization of human urinary metabolites of the antimalarial piperaquine.

J Tarning1, Y Bergqvist, N P Day, J Bergquist, B Arvidsson, N J White, M Ashton, N Lindegårdh.   

Abstract

Five metabolites of the antimalarial piperaquine (PQ) (1,3-bis-[4-(7-chloroquinolyl-4)-piperazinyl-1]-propane) have been identified and their molecular structures characterized. After a p.o. dose of dihydroartemisinin-piperaquine, urine collected over 16 h from two healthy subjects was analyzed using liquid chromatography (LC)/UV, LC/tandem mass spectrometry (MS/MS), Fourier transform ion cyclotron resonance (FTICR)/MS, and H NMR. Five different peaks were recognized as possible metabolites [M1, 320 m/z; M2, M3, and M4, 551 m/z (PQ + 16 m/z); and M5, 567 m/z (PQ + 32 m/z)] using LC/MS/MS with gradient elution. The proposed carboxylic M1 has a theoretical monoisotopic molecular mass of 320.1166 m/z, which is in accordance with the FTICR/MS (320.1168 m/z) findings. The LC/MS/MS results also showed a 551 m/z metabolite (M2) with a distinct difference both in polarity and fragmentation pattern compared with PQ, 7-hydroxypiperaquine, and the other 551 m/z metabolites. We suggest that this is caused by N-oxidation of PQ. The results showed two metabolites (M3 and M4) with a molecular ion at 551 m/z and similar fragmentation pattern as both PQ and 7-hydroxypiperaquine; therefore, they are likely to be hydroxylated PQ metabolites. The molecular structures of M1 and M2 were also confirmed using H NMR. Urinary excretion rate in one subject suggested a terminal elimination half-life of about 53 days for M1. Assuming formation rate-limiting kinetics, this would support recent findings that the terminal elimination half-life of PQ has been underestimated previously.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956956     DOI: 10.1124/dmd.106.011494

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers.

Authors:  Huixiang Liu; Hongchang Zhou; Tianyu Cai; Aijuan Yang; Meitong Zang; Jie Xing
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

2.  Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria.

Authors:  Elizabeth A Ashley; Kasia Stepniewska; Niklas Lindegardh; Anna Annerberg; Joel Tarning; Rose McGready; Lucy Phaiphun; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Eur J Clin Pharmacol       Date:  2010-03-19       Impact factor: 2.953

3.  Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria.

Authors:  J Tarning; I Zongo; F A Somé; N Rouamba; S Parikh; P J Rosenthal; W Hanpithakpong; N Jongrak; N P J Day; N J White; F Nosten; J-B Ouedraogo; N Lindegardh
Journal:  Clin Pharmacol Ther       Date:  2012-01-18       Impact factor: 6.875

4.  In vitro metabolism of piperaquine is primarily mediated by CYP3A4.

Authors:  Tina Ming-Na Lee; Liusheng Huang; Marla K Johnson; Patricia Lizak; Deanna Kroetz; Francesca Aweeka; Sunil Parikh
Journal:  Xenobiotica       Date:  2012-06-06       Impact factor: 1.908

5.  Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.

Authors:  Eva Maria Staehli Hodel; Chantal Csajka; Frédéric Ariey; Monia Guidi; Abdunoor Mulokozi Kabanywanyi; Socheat Duong; Laurent Arthur Decosterd; Piero Olliaro; Hans-Peter Beck; Blaise Genton
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

6.  Piperaquine pharmacodynamics and parasite viability in a murine malaria model.

Authors:  Brioni R Moore; Kenneth F Ilett; Madhu Page-Sharp; Jeffrey D Jago; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

Review 7.  Clinical pharmacology of artemisinin-based combination therapies.

Authors:  Polina I German; Francesca T Aweeka
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.

Authors:  J Tarning; E A Ashley; N Lindegardh; K Stepniewska; L Phaiphun; N P J Day; R McGready; M Ashton; F Nosten; N J White
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

9.  A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs.

Authors:  Eva Maria Hodel; Serej D Ley; Weihong Qi; Frédéric Ariey; Blaise Genton; Hans-Peter Beck
Journal:  Malar J       Date:  2009-12-09       Impact factor: 2.979

10.  Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.

Authors:  Eva Maria Staehli Hodel; Monia Guidi; Boris Zanolari; Thomas Mercier; Socheat Duong; Abdunoor M Kabanywanyi; Frédéric Ariey; Thierry Buclin; Hans-Peter Beck; Laurent A Decosterd; Piero Olliaro; Blaise Genton; Chantal Csajka
Journal:  Malar J       Date:  2013-07-10       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.